Benjamin R. Cowen
Director/Board Member bei INCON CO.,LTD.
Profil
Benjamin R.
Cowen is currently the President & Chief Executive Officer at ImmunoMet Therapeutics, Inc. He is also a Director at INCON Co., Ltd.
and has been a Director at Atrin Pharmaceuticals LLC since 2012.
Previously, he served as the Vice President-Corporate Development at Milestone Pharmaceuticals, Inc. Dr. Cowen holds an MBA degree from Carnegie Mellon University, which he obtained in 1997.
He also holds a doctorate degree from the University of Illinois, which he received in 1990.
Aktive Positionen von Benjamin R. Cowen
| Unternehmen | Position | Beginn |
|---|---|---|
| INCON CO.,LTD. | Director/Board Member | - |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Director/Board Member | 01.01.2012 |
ImmunoMet Therapeutics, Inc.
 ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImmunoMet Therapeutics, Inc. operates as a development-stage biopharmaceutical company that develops and commercializes novel oncology products. It offers novel technology that designed to disrupt cancer cell growth and enhance anti-cancer immunity. The company was founded in July 2015 and is headquartered in Houston, TX. | Chief Executive Officer | 01.11.2017 |
Ehemalige bekannte Positionen von Benjamin R. Cowen
| Unternehmen | Position | Ende |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Ausbildung von Benjamin R. Cowen
| Carnegie Mellon University | Masters Business Admin |
| University of Illinois | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MILESTONE PHARMACEUTICALS INC. | Health Technology |
| INCON CO.,LTD. | Consumer Durables |
| Private Unternehmen | 2 |
|---|---|
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Health Technology |
ImmunoMet Therapeutics, Inc.
ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImmunoMet Therapeutics, Inc. operates as a development-stage biopharmaceutical company that develops and commercializes novel oncology products. It offers novel technology that designed to disrupt cancer cell growth and enhance anti-cancer immunity. The company was founded in July 2015 and is headquartered in Houston, TX. | Health Technology |
